Research / NVDA / Fundamental state Inspectable configuration
State dimensions Filing 0001045810-21-000163 General Corporate
Debt relative to revenue RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.debt_to_revenue
154.08% · OPTIONAL · NOT_ENOUGH_HISTORY
Capex intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.capex_revenue_ratio
3.13% · OPTIONAL · NOT_ENOUGH_HISTORY
Operating cash generation RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
21.39% · OPTIONAL · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
50.30% · CORE · NOT_ENOUGH_HISTORY
Inventory pressure RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
31.44% · OPTIONAL · NOT_ENOUGH_HISTORY
Gross margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.gross_margin
65.20% · CORE · NOT_ENOUGH_HISTORY
Operating margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.operating_margin
37.60% · CORE · NOT_ENOUGH_HISTORY
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
19.75% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
7.87% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 25 states Self-history eligible
Oct 31, 2021 0/9 normalized Level 3 Jan 30, 2022 0/8 normalized Level 3 May 1, 2022 0/8 normalized Level 3 Jul 31, 2022 6/8 normalized Level 3 Oct 30, 2022 7/8 normalized Level 3 Jan 29, 2023 7/8 normalized Level 3 Apr 30, 2023 7/8 normalized Level 3 Jul 30, 2023 8/8 normalized Level 3 Oct 29, 2023 8/8 normalized Level 3 Jan 28, 2024 8/9 normalized Level 3 Apr 28, 2024 8/9 normalized Level 3 Jul 28, 2024 8/9 normalized Level 3 Oct 27, 2024 8/9 normalized Level 3 Jan 26, 2025 9/9 normalized Level 3 Apr 27, 2025 9/9 normalized Level 3 Jul 27, 2025 9/9 normalized Level 3 Oct 26, 2025 9/9 normalized Level 3 Jan 25, 2026 9/9 normalized Level 3 Apr 26, 2026 9/9 normalized Level 3 Jul 26, 2026 9/9 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 183.54%
Current 154.08%
Delta -29.47% Capex Intensity Increased
Previous 2.81%
Current 3.13%
Delta 0.31% Cash Generation Decreased
Previous 41.22%
Current 21.39%
Delta -19.83% Growth Decreased
Previous 68.31%
Current 50.30%
Delta -18.02% Inventory Pressure Decreased
Previous 32.49%
Current 31.44%
Delta -1.05% Margin Increased
Previous 64.78%
Current 65.20%
Delta 0.42% Profitability Increased
Previous 37.56%
Current 37.60%
Delta 0.04% R And D Intensity Increased
Previous 19.13%
Current 19.75%
Delta 0.62% Sbc Intensity Increased
Previous 7.15%
Current 7.87%
Delta 0.72% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.